ArticleChemSusChem2025
Scope and Limitations of the Use of Methanesulfonic Acid (MSA) as a Green Acid for Global Deprotection in Solid-Phase Peptide Synthesis.
Article in ChemSusChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative computational-experimental discovery and translation of antifungal peptides for multidrug-resistant fungi.Frontiers in microbiology · 2026Review
- Scope and Limitations of the Use of Methanesulfonic Acid (MSA) as a Green Acid for Global Deprotection in Solid-Phase Peptide Synthesis.ChemSusChem · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N,N-dimethylformamide (DMF) and trifluoroacetic acid (TFA) are the two solvents/reagents most widely used in solid-phase peptide synthesis (SPPS). While DMF is already regulated in Europe, TFA - a member of the polyfluoroalkyl substances (PFAS) family - is expected to face similar restrictions soon. These compounds break down slowly and pose risks to human health and the environment. Herein, the use of the so-called "green acid par excellence", methanesulfonic acid (MSA), in substitution of TFA is discussed. As MSA is stronger than TFA, it is diluted with a solvent for use. The effectivity of MSA depends on the solvents used. When dichloromethane (DCM) is used, 1.5 % MSA removes all side-chain protecting groups, except the trityl (Trt) group of His. In the presence of acetic acid (AcOH) and dimethylcarbonate (DMC), more concentrated solutions of MSA (8-16 %) are required. The removal of the Trt group of Asn/Gln continues to be a challenge even with these solutions, and aspartimide formation can occur in Asp-containing peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.